Literature DB >> 28257661

Alisol B 23-acetate from the rhizomes of Alisma orientale is a natural agonist of the human pregnane X receptor.

Yuichiro Kanno1, Tomofumi Yatsu2, Naoya Yamashita2, Shuai Zhao2, Wei Li3, Miyuki Imai4, Manami Kashima4, Yoshio Inouye2, Kiyomitsu Nemoto2, Kazuo Koike4.   

Abstract

BACKGROUND: Pregnane X receptor (PXR) is a key regulator of the induction of drug metabolizing enzymes. PXR has been studied for its importance in drug-drug or herb-drug interactions, and it is also a molecular target for the treatment of inflammatory and metabolic diseases.
PURPOSE: This study aims to determine new natural PXR-ligands from traditional plant medicines.
METHODS: The PXR activation activity was measured by a mammalian one hybrid assay of PXR. Identification of the active compound from Alisma rhizome (the rhizomes of Alisma orientale) was carried out by bioassay-guided fractionation method. The transcriptional activity of the liver-enriched nuclear receptors was measured by the luciferase reporter assay. The interaction between the SRC-1 and PXR was measured by a mammalian 2-hybrid assay. The expression of endogenous CYP3A4 mRNA in both cultured hPXR-overexpressing hepatoma cells and human primary hepatocytes were measured by quantitative RT-PCR method.
RESULTS: The extract of Alisma rhizome showed the most potent activation activity by screening of a library of medicinal plant extracts. Alisol B 23-acetate (ABA) was identified to be the active compound of Alisma rhizome. ABA caused a concentration-dependent increase on the PXR-dependent transactivation of a luciferase reporter gene, but did not affect the ligand binding activity of the liver-enriched nuclear receptors, such as CAR, LXR, FXR, PPARα, PPARδ and PPARγ, emphasizing that ABA is a potent and specific agonist of PXR. With ABA treatment, the direct interaction between the ligand-binding domain of PXR and the receptor interaction domain of SRC1 was observed. ABA also induced the expression of endogenous CYP3A4 mRNA in both cultured hPXR-overexpressing hepatoma cells and human primary hepatocytes.
CONCLUSION: Since the rhizomes of Alisma orientale are used for a wide range of ailments in traditional Chinese medicine and Japanese Kampo medicine, this study could possibly extend into the clinical usage of these medicines via the mechanism of PXR activation.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Alisma orientale; Alisma rhizome; Alisol B 23-acetate; Nuclear receptor; Pregnane X receptor

Mesh:

Substances:

Year:  2017        PMID: 28257661     DOI: 10.1016/j.phymed.2017.01.003

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  5 in total

1.  Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice.

Authors:  Zhuohui Zhao; Zhen-Tao Deng; Suling Huang; Mengmeng Ning; Ying Feng; Yu Shen; Qin-Shi Zhao; Ying Leng
Journal:  Nutrients       Date:  2022-06-10       Impact factor: 6.706

Review 2.  Regulation of PXR Function by Coactivator and Corepressor Proteins: Ligand Binding Is Just the Beginning.

Authors:  Juan Pablo Rigalli; Dirk Theile; Julie Nilles; Johanna Weiss
Journal:  Cells       Date:  2021-11-12       Impact factor: 6.600

Review 3.  Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma.

Authors:  Christian Bailly
Journal:  Biomedicines       Date:  2022-08-11

Review 4.  Update on FXR Biology: Promising Therapeutic Target?

Authors:  Chang Yeob Han
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

5.  Qualitative Analysis of Drug-Containing Plasma and its Application to Quantitative Analysis and Pharmacokinetic Study of Zexie Decoction Using UPLC-MS/MS.

Authors:  Jiashuo Wu; Shunliang Zheng; Fangqing Zhang; Haonan Ruan; Haotian Xue; Jingxun Wang; Zhuangzhuang Li; Weiyi Jin; Weihua Wang; Jing Xia; Yue Shi
Journal:  Front Chem       Date:  2022-02-22       Impact factor: 5.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.